ChromaDex Corporation (CDXC) ニュース

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16...

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference...

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that...

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that...

ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

Tru Niagen is now available to US troops through an exclusive Military program ChromaDex Corp. (NASDAQ:CDXC), the global authority on...

Form 8-K - Current report

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+ PR...

Form 4 - Statement of changes in beneficial ownership of securities

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

Building on a growing body of research showcasing NR as a potential therapeutic strategy for PD, this is the first clinical study to showcase the...

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

This is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR...

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023

ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today...